Fulgent Genetics, Inc. (FLGT) Stock
FLGT Key Statistics
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
CEO: Ming Hsieh. Company website
FLGT — Frequently Asked Questions
What is the FLGT stock price today?
Fulgent Genetics, Inc. (FLGT) trades at $21.69, down 0.73% on the day, as of Sep 20, 2026 15:00 UTC.
What is Fulgent Genetics, Inc.'s market cap?
Fulgent Genetics, Inc. has a market capitalisation of $616.01M, calculated from the live FLGT share price and shares outstanding.
What is the P/E ratio of FLGT?
FLGT has no meaningful price-to-earnings ratio: Fulgent Genetics, Inc. lost $2.82 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Fulgent Genetics, Inc. make?
Fulgent Genetics, Inc. generated revenue of $323.93M over the trailing twelve months, which puts the stock at 1.90 times sales.
What is the 52-week range for FLGT?
FLGT has traded between $13.46 and $31.04 over the past 52 weeks, and the last price is 30.1% below that high.
Is Fulgent Genetics, Inc. profitable?
No. Fulgent Genetics, Inc. is loss-making, with a net margin of -26.05% over the trailing twelve months.
What is the analyst price target for FLGT?
Wall Street analysts rate FLGT Buy, with an average price target of $19.00, 12.4% below the current price.
What sector is Fulgent Genetics, Inc. in?
Fulgent Genetics, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Fulgent Genetics, Inc.?
Ming Hsieh is the chief executive of Fulgent Genetics, Inc., which employs 1,315 people.
Where can I track FLGT in real time?
QFI Terminal shows FLGT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See FLGT live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FLGT in Terminal See plans